Lifecore Biomedical LLC

Primary Objective: To demonstrate that KSI-301 5 mg is non-inferior to aflibercept 2 mg in achieving mean change in BCVA from study day 1 to year 1 (average of weeks 48 and 52). Secondary Objectives: To evaluate the efficacy of KSI-301 5 mg compared to aflibercept 2 mg during the study by assessing visual parameters. To evaluate the efficacy of KSI-301 5 mg compared to aflibercept 2 mg during the study by assessing anatomical parameters. To assess the durability of the efficacy of KSI-301 5 mg compared to aflibercept 2 mg during the study. To assess the safety and tolerability of KSI-301 5 mg compared to aflibercept 2 mg.

Primary Objectives: Demonstrate that KSI-301 5 mg administered every 8 weeks (starting after 2 months of monthly dosing) is non-inferior to aflibercept 2 mg administered monthly in mean change in best corrected visual acuity (BCVA) from day 1 to week 24. Secondary Objectives: To evaluate the efficacy of KSI-301 5 mg compared to aflibercept 2 mg during the study period by assessing visual acuity and anatomical parameters. To assess the persistence of KSI-301 5 mg compared to aflibercept during the study period. To assess the safety and tolerability of KSI-301 5 mg compared to aflibercept 2 mg.